Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

May 21, 2024 Virtual Tumor Board: PD-L1 Low NSCLC
In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC.
Dr. Apar Ganti is a Professor of Medicine at the University of Nebraska Medical Center and the Associate Director for Clinical Research at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska.
Dr. Sze-Wai Chan from the Sandton Oncology Centre in Johannesburg, South Africa, where she is the Director and Head of Clinical Trial Research.
34 min
May 07, 2024 When two worlds collide: Adenosquamous histology
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnosis, treatment, and outcomes in this group of patients.
40 min
April 30, 2024 KRAS in NSCLC: Beyond G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all forms of KRAS mutant lung cancers are the same and clinicians need to be aware of the difference between KRAS mutations.
47 min
April 18, 2024 FDA Approval: Adjuvant Alectinib for Resected NSCLC
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
39 min
April 16, 2024 IASLC DEI Initiative Global Member Survey
As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed to help the organization better understand the challenges and areas for opportunity facing the global thoracic oncology profession. To take the survey, visit: https://www.iaslc.org/support-mission/iaslc-dei-initiative-global-member-surve
28 min
April 02, 2024 FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.
48 min
March 28, 2024 ELCC 2024 Highlights
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with Dr. Jeff Bradley, Dr. Hazel O’Sullivan, and Dr. Antonio Calles.
59 min
March 19, 2024 Emerging Agents In Small Cell Lung Cancer
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fortunately, the field continues to advance and there are several novel agents showing promise. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses some of these promising therapies with Dr. Anne Chiang and Dr. Luis Paz-Ares.
42 min
March 05, 2024 Radiopharmaceuticals and Lung Cancer
This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.
55 min
March 01, 2024 FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Amivantamab Approved by FDA today, March 1!
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.
29 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.